BAY-747   Click here for help

GtoPdb Ligand ID: 12763

Synonyms: BAY 1165747 [2] | BAY747 | compound 28 [PMID: 37040336]
Compound class: Synthetic organic
Comment: BAY-747 is an orally active and brain-penetrant soluble guanylyl cyclase (sGC) stimulator [2-3]. It was developed to treat resistant hypertension. It has also been suggested as a potential therapy for Duchenne muscular dystrophy, that is proposed to improve skeletal muscle function via activation of the NO-sGC-cGMP pathway [1]
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 79.95
Molecular weight 416.47
XLogP 2.22
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC[C@@](C)(CNC(=O)C1=C(C)N=C2C(=CC(=CN12)C)OCC3=C(C=CC=C3F)F)N
Isomeric SMILES CC[C@@](C)(CNC(=O)C1=C(N=C2N1C=C(C=C2OCC3=C(C=CC=C3F)F)C)C)N
InChI InChI=1S/C22H26F2N4O2/c1-5-22(4,25)12-26-21(29)19-14(3)27-20-18(9-13(2)10-28(19)20)30-11-15-16(23)7-6-8-17(15)24/h6-10H,5,11-12,25H2,1-4H3,(H,26,29)/t22-/m0/s1
InChI Key MITNUFZPBQIMAT-QFIPXVFZSA-N
References
1. Krishnan SM, Nordlohne J, Dietz L, Vakalopoulos A, Haning P, Hartmann E, Seifert R, Hüser J, Mathar I, Sandner P. (2021)
Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy.
Int J Mol Sci, 22 (15). DOI: 10.3390/ijms22158016 [PMID:34360780]
2. Vakalopoulos A, Wunder F, Hartung IV, Redlich G, Jautelat R, Buchgraber P, Hassfeld J, Gromov AV, Lindner N, Bierer D et al.. (2023)
New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.
J Med Chem, 66 (11): 7280-7303. [PMID:37040336]
3. Wunder F, Stasch JP, Knorr A, Mondritzki T, Brockschnieder D, Becker-Pelster EM, Sandner P, Tinel H, Redlich G, Hartung IV et al.. (2023)
Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.
Br J Pharmacol, 180 (19): 2500-2513. [PMID:37170767]